Cue Biopharma Stock Quote CUE - Stock Price, News, Charts, Message Board, Trades

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Premium

Current Price

1.31

Bid

1.23

Ask

1.37

Volume

331,762

1.26 Day's Range 1.37

1.26 52 Week Range 4.89

Market Cap

66.641M

Previous Close

1.30

Open

1.30

Last Trade

1.31

Last Trade Time

Financial Volume

$ 435,135

VWAP

1.3116

Average Volume (3m)

287,020

Shares Outstanding

48,643,316

Dividend Yield

PE Ratio

-1.31

Earnings Per Share (EPS)

-1.04

Revenue

5.49M

Net Profit

-50.73M

Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its lead drug candidate comprises CUE-101, a variant ... Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its lead drug candidate comprises CUE-101, a variant form of the cytokine Interleukin-2 and a T cell antigen to target and activate T cells specific to HPV-related cancers. The other products under pipeline are CUE-102, CUE-103, CUE-400, and CUE-401. Show more

Sector

Pharmaceutical Preparations

Industry

Pharmaceutical Preparations

Website

www.cuebiopharma.com

Headquarters

Wilmington, Delaware, USA

Founded

1970

Cue Biopharma Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker CUE. The last closing price for Cue Biopharma was $1.30. Over the last year, Cue Biopharma shares have traded in a share price range of $ 1.26 to $ 4.89.

Cue Biopharma currently has 48,643,316 shares outstanding. The market capitalization of Cue Biopharma is $66.64 million. Cue Biopharma has a price to earnings ratio (PE ratio) of -1.31.

Form 8-K - Current report

Form 4 - Statement of changes in beneficial ownership of securities

Cue Biopharma Presents Updated Data from Phase 1 Trial of CUE-101 in Recurrent/Metastatic HPV+ Head and Neck Cancer at the 2024 ASCO Annual Meeting

Overall response rate (ORR) of 46% and 12-month overall survival (OS) of 96% in first line (1L) recurrent/metastatic (R/M) HPV+ head and neck squamous cell carcinoma (HNSCC) treated with CUE-101...

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	-0.25	-16.0256410256	1.56	1.56	1.26	292084	1.34177375	CS
4	-0.44	-25.1428571429	1.75	1.79	1.26	246171	1.50174772	CS
12	-0.62	-32.1243523316	1.93	2.26	1.26	287020	1.71208835	CS
26	-1.55	-54.1958041958	2.86	3.2	1.26	282268	2.10626209	CS
52	-2.7	-67.3316708229	4.01	4.89	1.26	343125	2.70757046	CS
156	-11.34	-89.6442687747	12.65	18.42	1.26	302775	5.1580125	CS
260	-6.07	-82.2493224932	7.38	35.5	1.26	290421	9.26766043	CS

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
AREBAmerican Rebel Holdings Inc	$ 0.76 (152.49%)	371.46M
SHCRSharecare Inc	$ 1.365 (76.27%)	56.33M
NXLNexalin Technologies Inc	$ 1.7499 (59.08%)	57.58M
FUFUBitFuFu Inc	$ 6.1209 (56.95%)	2.5M
SPECSpectaire Holdings Inc	$ 0.50 (47.06%)	65.27M
FLFVFeutune Light Acquisition Corporation	$ 2.5502 (-69.75%)	862.38k
FLFVUFeutune Light Acquisition Corporation	$ 2.75 (-66.83%)	16.5k
RWODRedwoods Acquisition Corporation	$ 2.34 (-60.34%)	155.96k
KAVLKaival Brands Innovations Group Inc	$ 1.23 (-57.14%)	4.92M
RWODURedwoods Acquisition Corporation	$ 3.24 (-56.28%)	1.47k
NVDANVIDIA Corporation	$ 126.57 (-3.22%)	658.13M
AREBAmerican Rebel Holdings Inc	$ 0.76 (152.49%)	371.46M
SIRISirius XM Holdings Inc	$ 2.94 (1.38%)	330.66M
AAPLApple Inc	$ 207.49 (-1.04%)	246.38M
NKLANikola Corporation	$ 0.3466 (5.16%)	193.36M